CACI International Inc (NYSE:CACI) announced today that its Board of Directors has authorized the repurchase of up to $750 million of its common stock.
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars
Moderna reports Q1 loss, beating sales estimates amidst declining COVID-19 vaccine demand. Cost-saving measures drive optimism for investors. CEO Stéphane Bancel eyes strategic investments. Guidance reaffirms $4 billion sales target for 2024.